Jim Simons
SABS icon

Jim Simons’s SAB Biotherapeutics SABS Stock Holding History

Jim Simons’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80,840
Closed -$162K – 3686
2025
Q3 		$162K Buy
80,840
+69,810
+633% +$158K ﹤0.01% 3175
2025
Q2 		$19.4K Buy
11,030
+1,000
+10% +$1.66K ﹤0.01% 3472
2025
Q1 		$13.6K Buy
+10,030
New +$23K ﹤0.01% 3377
2024
Q1 		– Sell
-6,310
Closed -$43K – 4016
2023
Q4 		$43K Buy
6,310
+500
+9% +$4.19K ﹤0.01% 3478
2023
Q3 		$37K Buy
5,810
+370
+7% +$2.72K ﹤0.01% 3443
2023
Q2 		$45K Buy
+5,440
New +$44.6K ﹤0.01% 3637

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Jim Simons's SABS Position: Q4 2025 in Review

Jim Simons sold out of SAB Biotherapeutics (SABS) in Q4 2025, closing a stake of 80,840 shares — an estimated $162K sold.

Jim Simons first reported a position in SABS in Q2 2023 and held it in 6 quarters. The position peaked at $162K in Q3 2025. 48 funds tracked by Wall St. Rank hold SABS as of Q4 2025.

  • Jim Simons reported no remaining SAB Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Jim Simons sold 80,840 SAB Biotherapeutics shares in Q4 2025, an estimated $162K.
  • Jim Simons first reported a position in SAB Biotherapeutics in Q2 2023 and held it in 6 quarters.
  • Jim Simons's SAB Biotherapeutics position peaked at $162K in Q3 2025.
  • 48 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.